>> Eurofins US News >> Eurofins Appoints New President for US Microbiology Division

Eurofins Appoints New President for US Microbiology Division

Sidebar Image

Des Moines, IA, August 2, 2016

Eurofins Scientific announces the appointment of Kally Probasco, President, Eurofins Microbiology
Laboratory (EML).

Ms. Probasco will provide dynamic new leadership to Eurofins’ rapidly expanding national network
of local food microbiology laboratories.

Before her appointment, Ms. Probasco oversaw all US operational functions for the EML group
involving successful installations of technical methodologies, strategic account negotiations, key
talent acquisition, new lab constructions, and other key initiatives. She was instrumental in the
achievement of aggressive growth objectives and quality standards for the division.

She has a Bachelor of Science degree from Iowa State University in Biochemistry and has
accumulated vital experience in all aspects of laboratory operations for Eurofins over the years.
David Bryant, Senior Vice President of Eurofins North America, Food and Environment Testing
said, “We are delighted to have Kally in this important role in our organization as she brings a
tremendous amount of energy and strategic leadership to our growing and talented group of food
safety testing professionals. In light of the demands that are being placed on food producers,
processors, and importers for food safety compliance, we understand how important it is to be a
stakeholder in the success of our customers and provide them with cutting edge analytical
technologies and unparalleled service to help them meet their challenges with ease and
personalized support.”

Today, Eurofins provides a complete array of services in the area of food safety that include
comprehensive microbiological testing, a wide array of contaminant detection assays, import
detention testing, food safety auditing according to globally recognized and benchmarked industry
standards, and an expanding offering of food safety training courses. With recent advancements in
microbiomics and innovative logistical solutions, Eurofins continues to enhance its unmatched
portfolio of assays and develop new ways to provide customers with greater understanding of their
processes and an improved ability to meet their product quality demands in less time.

For more information, visit or email

Notes for the editor:

Eurofins – a global leader in bio-analysis
Eurofins Scientific believes it is the world leader in food, environment and pharmaceutical products testing, as well as
one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services. In
addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA.
With over 23,000 staff in more than 225 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000
validated analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability and purity
of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers
with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of
biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive
range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to
support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory
authorities and healthcare practitioners around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters
EUFI.PA, Bloomberg ERF FP).

Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The
forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific as of the date
of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking
events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of
these forward-looking statements and estimates. All statements and estimates are made based on the data available
to the Company as of the date of publication, but no guarantee can be made as to their validity.